Chamorro-Petronacci C, García-García A, Lorenzo-Pouso AI, Gómez-García FJ, Padín-Iruegas ME, Gándara-Vila P, Blanco-Carrión A, Pérez-Sayáns M. Management options for low-dose methotrexate-induced oral ulcers: A systematic review. Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24 (2):e181-9.

 

doi:10.4317/medoral.22851

http://dx.doi.org/doi:10.4317/medoral.22851

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

 

References

1. Lee HJ, Hong SK, Seo JK, Lee D, Sung HS. A Case of Cutaneous Side Effect of Methotrexate Mimicking Behcet's Disease. Ann Dermatol. 2011;23:412-4.
https://doi.org/10.5021/ad.2011.23.3.412
PMid:21909222 PMCid:PMC3162281

 

 

2. Katsoulas N, Chrysomali E, Piperi E, Levidou G, Sklavounou-Andrikopoulou A. Atypical methotrexate ulcerative stomatitis with features of lymphoproliferative like disorder: Report of a rare ciprofloxacin-induced case and review of the literature. J Clin Exp Dent. 2016;8:e633.
https://doi.org/10.4317/jced.52909

 

3. West J, Ogston S, Foerster J. Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials. PLoS One. 2016;11:e0153740.
https://doi.org/10.1371/journal.pone.0153740
PMid:27168193 PMCid:PMC4864230

 

4. Franova J, Fingerhutova S, Kobrova K, Srp R, Nemcova D, Hoza J, et al. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. Pediatr Rheumatol Online J. 2016;14:36.
https://doi.org/10.1186/s12969-016-0099-z
PMid:27301536 PMCid:PMC4908704

 

5. Souza CF, Suarez OM, Silva TF, Gorenstein AC, Quintella LP, Avelleira JC. Ulcerations due to methotrexate toxicity in a psoriasis patient. An Bras Dermatol. 2016;91:375-7.
https://doi.org/10.1590/abd1806-4841.20163960
PMid:27438211 PMCid:PMC4938288

 

6. Yelamos O, Catala A, Vilarrasa E, Roe E, Puig L. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. Dermatology. 2014;229:306-9.
https://doi.org/10.1159/000366501
PMid:25401478

 

7. Delyon J, Ortonne N, Benayoun E, Moroch J, Wolkenstein P, Sbidian E, et al. Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker. J Am Acad Dermatol. 2015;73:484-90.
https://doi.org/10.1016/j.jaad.2015.06.015
PMid:26190242

 

8. Kalantzis A, Marshman Z, Falconer DT, Morgan PR, Odell EW. Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:52-62.
https://doi.org/10.1016/j.tripleo.2004.08.020
PMid:15953917

 

9. Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev. 2014;13:1109-13.
https://doi.org/10.1016/j.autrev.2014.08.027
PMid:25172240

 

10. Samarasekera E, Sawyer L, Parnham J, Smith CH, Guideline Development Group. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712.
https://doi.org/10.1136/bmj.e6712
PMid:23097521

 

11. Ferrandiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr. 2014;105:504-9.
https://doi.org/10.1016/j.adengl.2014.04.016

 

12. Aslam S, Emmanuel P, Formulating a researchable question: A critical step for facilitating good clinical research. Indian J Sex Transm Dis AIDS. 2010;31:47-50.
https://doi.org/10.4103/0253-7184.69003
PMid:21808439

 

13. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23:60-3.
https://doi.org/10.1136/bmjebm-2017-110853
PMid:29420178 PMCid:PMC6234235

 

14. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379:1310-9.
https://doi.org/10.1016/S0140-6736(11)61817-5

 

15. Li W, Zeng S, Yu LS, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013;9:259-71.

 

16. Deeming GM, Collingwood J, Pemberton MN. Methotrexate and oral ulceration. Br Dent J. 2005 Jan 22;198:83-5.
https://doi.org/10.1038/sj.bdj.4811972
PMid:15702101

 

17. Horie N, Kawano R, Kaneko T, Shimoyama T. Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis. Aust Dent J. 2015;60:408-11.
https://doi.org/10.1111/adj.12235
PMid:25302816

 

18. Kudoh M, Harada H, Matsumoto K, Sato Y, Omura K, Ishii Y. Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:105.
https://doi.org/10.1016/j.oooo.2014.02.029
PMid:24811204

 

19. Hanakawa H, Orita Y, Sato Y, Uno K, Nishizaki K, Yoshino T. Large ulceration of the oropharynx induced by methotrexate-associated lymphoproliferative disorders. Acta Med Okayama. 2013;67:265-9.
PMid:23970326

 

20. Pastor-Nieto MA, Kilmurray LG, Lopez-Chumillas A, O'Valle F, Garcia-Del Moral R, Puig AM, et al. Methotrexate-associated lymphoproliferative disorder presenting as oral ulcers in a patient with rheumatoid arthritis. Actas Dermosifiliogr. 2009;100:142-6.
https://doi.org/10.1016/S0001-7310(09)70233-9

 

21. Troeltzsch M, von Blohn G, Kriegelstein S, Woodlock T, Gassling V, Berndt R, et al. Oral mucositis in patients receiving low-dose methotrexate therapy for rheumatoid arthritis: report of 2 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:28.
https://doi.org/10.1016/j.oooo.2012.12.008
PMid:23601229

 

22. Ongaro A, De Mattei M, Della Porta MG, Rigolin G, Ambrosio C, Di Raimondo F, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94:1391-8.
https://doi.org/10.3324/haematol.2009.008326
PMid:19648163 PMCid:PMC2754955

 

23. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34:405-17.
https://doi.org/10.1097/PAS.0b013e3181cf8622
PMid:20154586

 

24. Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013:CD000951.

 

25. Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, et al. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant. 2012;47:258-64.
https://doi.org/10.1038/bmt.2011.53
PMid:21423118

 

26. Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol. 1996;35:835-8.
https://doi.org/10.1016/S0190-9622(96)90097-3

 

27. Lobel U, Trah J, Escherich G. Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:539-41.
https://doi.org/10.1002/pbc.25270
PMid:25360802